Lixte Biotechnology receives Nasdaq deficiency notice for stockholders' equity requirement

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Received Notice from Nasdaq on August 19, 2024 for non-compliance with Listing Rule 5550(b)(1) requiring minimum $2,500,000 stockholders' equity.
Company has 45 days to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.
If plan not accepted or compliance not regained, Company can request hearing which stays suspension or delisting.
Trading on Nasdaq continues under symbols LIXT and LIXTW with no immediate effect.
Company intends to take reasonable measures but no assurance of regaining compliance with continued listing standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.